Program
BI 3810477
A development code.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Boehringer Ingelheim.
Furthest: phase 2, since Nov 3, 20263 company-led studies, 1 open or runningNext primary completion: Jan 27, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 31 open or running | phase 2since Nov 3, 2026 | Oct 7, 2024 | Jan 27, 2028phase 2 · NCT07926321 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 7, 2024First study: phase 1 study in HealthyFirst studyNCT06631430 · 24 enrolled · Belgium
- May 15, 2025Phase 1 study in HealthyNCT06984926 · 47 enrolled · Belgium
- Nov 3, 2026Phase 2 study in Idiopathic Pulmonary FibrosisPhase 2 reachedNCT07926321 · 70 planned · United States, Belgium, Finland and more
Ahead
- Jan 27, 2028Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT07926321
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07926321Idiopathic Pulmonary Fibrosis · United States, Belgium, Finland and more | 2 | Not yet recruiting | Jan 27, 2028 | 70 |
| NCT06984926Healthy · Belgium | 1 | Completed | Mar 9, 2026 | 47 |
| NCT06631430Healthy · Belgium | 1 | Completed | Jun 12, 2025 | 24 |
How it is read
Names in the registry
- “BI 3810477”, 4 entries
Codes read as this program: BI3810477.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.